Mapp Biopharmaceutical
6160 Lusk Boulevard
Suite C105
San Diego
California
92121
United States
Tel: 858-625-0335
Fax: 800-372-2176
Website: http://www.mappbio.com/
Email: admin@mappbio.com
14 articles about Mapp Biopharmaceutical
-
DCN Dx and Mapp Biopharmaceutical Announce Subcontract
2/1/2023
DCN Dx announced a subcontract with Mapp Biopharmaceutical, Inc., a developer of novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.
-
Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical
12/5/2022
Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, signed an exclusive term sheet to secure international development and global commercial rights upon licensure for the pan-Ebola and pan-Marburg monoclonal antibody (mAbs) programs from Mapp Biopharmaceutical, Inc.
-
Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.
-
As Deadliest Strain Ravages Country, Four Experimental Ebola Vaccines to Be Deployed in the Congo
11/12/2018
As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials has taken four experimental vaccines to the front lines and begun to administer it to patients who may have been exposed to the deadly virus. -
ClinicalRM (formerly known as Clinical Research Management) And Mapp Biopharmal Combine Efforts To Continue The Fight Against Ebola
8/9/2016
-
Mapp Biopharma Scientists Try To Stop Another Deadly Virus
4/5/2016
-
Nascent Biotech Announces $225,000 NIH Grant Award In Conjunction With Mapp Biopharmaceutical
2/26/2015
-
Drugmakers Like Johnson & Johnson, Emergent BioSolutions, And Mapp Biopharmaceutical Stand To Gain Ebola Contracts Worth $2 Billion
11/11/2014
-
Ebola Clinical Trials: Big Name Players In The Ebola Race
10/28/2014
-
U.S. Regulators Ask Three Labs For Mapp Biopharmaceutical's ZMapp Ebola Plans
10/20/2014
-
Amgen Will Assign 12 To 14 Staff Members To Look Into An Alternative Production Method For Mapp Biopharmaceutical's ZMapp
10/20/2014
-
Mapp Biopharmaceutical's Ebola Drug Production Set for Texas, Possibly North Carolina
9/30/2014
-
Feds To Provide As Much As $42.3 Million To Tiny San Diego-Based Mapp Biopharmaceutical
9/3/2014
-
"Plantibodies" Drugs Made From Small Biotechs Like Mapp Biopharmaceuticals Advance As Big Pharma Stands Aside
8/18/2014